Companies bought, from Dealroom; bubbles sized by the price where one was disclosed
1 acquisition
$85M disclosed
7 acquisitions
$2.6B disclosed, 3 undisclosed
2020
2021
2022
2023
2024
2025
2026
Moderna
OriCiro Genomics · $85M · Jan 2023 · Cell-free synthesis of large DNA for mRNA manufacturing
OriCiro Genomics
$85M · Jan 2023
Manufacturing technology
BioNTech
Neon Therapeutics · $67M · Jan 2020 · Neoantigen cancer vaccines and T-cell therapies · all-stock
Neon Therapeutics
$67M · Jan 2020
Cancer immunotherapy · all-stock
PhagoMed Biopharma · Undisclosed · Nov 2021 · Phage and endolysin anti-infectives
PhagoMed Biopharma
Undisclosed · Nov 2021
Anti-infectives
InstaDeep · $442M · Jan 2023 · AI and machine learning for drug discovery; up to £562M with milestones. BioNTech had joined InstaDeep's Series B a year earlier · £362M upfront
InstaDeep
$442M · Jan 2023
AI · £362M upfront
AexeRNA Therapeutics · Undisclosed · Nov 2023 · Lipid nanoparticle delivery for mRNA
AexeRNA Therapeutics
Undisclosed · Nov 2023
mRNA delivery
CellmAbs · Undisclosed · Jul 2024 · Glycan-targeting cancer antibodies
CellmAbs
Undisclosed · Jul 2024
Antibodies
Biotheus · $800M · Nov 2024 · Bispecific antibodies, including full rights to pumitamig (BNT327); up to $150M more in milestones · $800M upfront
Biotheus
$800M · Nov 2024
Antibodies · $800M upfront
CureVac · $1.3B · Jun 2025 · mRNA platform, patents and manufacturing; announced June 2025 · all-stock
CureVac
$1.3B · Jun 2025
mRNA platform · all-stock
Swipe sideways to see the whole timeline →